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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERWhat Do We Know About the “Malignant Form” of Early Repolarization? 863Arnon Adler, Raphael Rosso, Dana Viskin, Amir Halkin, Sami Viskin
There is an urgent need to identify electrocardiographic characteristics that differentiate the
“benign early repolarization pattern” from “malignant early repolarization.” Adler and
colleagues review recent evidence regarding the prognostic importance of the contour of the
ST-segment. A rapidly ascending ST-segment portends a benign prognosis, whereas a ﬂat or
horizontal ST-segment appears to be associated with an increased risk of sudden cardiac
death.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYPrognostic Value of CKD After TAVI 869Masanori Yamamoto, Kentaro Hayashida, Gauthier Mouillet, Thomas Hovasse, Bernard Chevalier,
Atsushi Oguri, Yusuke Watanabe, Jean-Luc Dubois-Randé, Marie-Claude Morice, Thierry Lefèvre,
Emmanuel Teiger
Yamamoto and colleagues assessed the inﬂuence of chronic kidney disease (CKD) on clinical
outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Both the
30-day and cumulative 1-year mortality rates were signiﬁcantly associated with the degree of
renal dysfunction. After adjustment for considerable inﬂuential confounders in a Cox-
regression multivariate model, CKD stage 4 was associated with a 3 times higher risk of 30-
day mortality compared with CKD stage 1 or 2. These results show the strong negative
prognostic impact of CKD on mortality after TAVI.
Editorial Comment: Olaf Wendler, Philip MacCarthy, p. 878(continued on page A-26)
SEPTEMBER 3, 2013 (continued) A-26HEART FAILUREPatients With HF Have an Increased Risk of Incident Cancer 881
Tal Hasin, Yariv Gerber, Sheila M. McNallan, Susan A. Weston, Sudhir S. Kushwaha,
Timothy J. Nelson, James R. Cerhan, Veronique L. Roger
In a case-control study, Hasin and colleagues compared the risk of cancer among community
subjects newly diagnosed with heart failure (HF) with age-, sex-, and date-matched
community controls without HF. Before the diagnosis of HF, 22% of HF cases and 23% of
control patients had a history of cancer. During 9,203 person-years of follow-up, HF patients
had a 68% higher risk of developing cancer. These results suggest that either HF or its
treatment increases the risk of cancer, and further investigation appears warranted.
Editorial Comment: Anita Deswal, Sukhdeep S. Basra, p. 887HEART RHYTHM DISORDERSValidation of a Novel 3D ECM of AT 889
Ashok J. Shah, Meleze Hocini, Olivier Xhaet, Patrizio Pascale, Laurent Roten, Stephen B. Wilton,
Nick Linton, Daniel Scherr, Shinsuke Miyazaki, Amir S. Jadidi, Xingpeng Liu, Andrei Forclaz,
Isabelle Nault, Lena Rivard, Michala E. F. Pedersen, Nicolas Derval, Frederic Sacher, Sebastien Knecht,
Pierre Jais, Remi Dubois, Sandra Eliautou, Ryan Bokan, Maria Strom, Charu Ramanathan,
Ivan Cakulev, Jayakumar Sahadevan, Bruce Lindsay, Albert L. Waldo, Michel Haissaguerre
Shah and colleagues prospectively evaluated the utility of a novel 3-dimensional (3D),
noninvasive, beat-by-beat mapping system for facilitating the diagnosis of atrial tachycardia
(AT). The electrocardiographic mapping (ECM) consisted of recording body surface
electrograms from a 252-electrode vest placed on the torso combined with computed
tomography scan-based biatrial anatomy. The ECM was followed by standard of care
electrophysiological mapping and ablation in 52 patients with ATs. The ECM correctly
diagnosed AT mechanisms in 92% of subjects as either macro–re-entry or focal-onset with
centrifugal activation. The region of interest for focal ATs perfectly matched the ECM
prediction in 100% of subjects. This ECM technique may be useful for noninvasively
diagnosing the mechanism of AT and the location of focal arrhythmia.
Editorial Comment: Melvin Scheinman, Edward Gerstenfeld, p. 898(continued on page A-27)
SEPTEMBER 3, 2013 (continued) A-27HEART RHYTHM DISORDERSBalancing the Beneﬁts and Risks of 2 Doses of Dabigatran 900
John W. Eikelboom, Stuart J. Connolly, Robert G. Hart, Lars Wallentin, Paul Reilly, Jonas Oldgren,
Sean Yang, Salim Yusuf
In patients with atrial ﬁbrillation (AF), dabigatran 110 mg twice a day (bid) and 150 mg bid
are associated with similar rates of death; however, the higher dose reduces ischemic stroke
and increases bleeding compared with the lower dose. Eikelboom and colleagues developed a
method for integrating ischemic and bleeding events as “ischemic stroke equivalents,” based
on their associated mortality, to compare the relative beneﬁts of the 2 doses of dabigatran
with each other and with warfarin. Compared with warfarin, both dabigatran doses resulted
in a signiﬁcant decrease in ischemic stroke equivalents, but there was no difference between
the 2 doses. The higher mortality risk associated with ischemic stroke than major bleeding
underlies these results.CARDIAC IMAGINGIntense Statin Therapy Results in a Rapid Reduction in
Atherosclerotic Inﬂammation909Ahmed Tawakol, Zahi A. Fayad, Robin Mogg, Achilles Alon, Michael T. Klimas, Hayes Dansky,
Sharath S. Subramanian, Amr Abdelbaky, James H. F. Rudd, Michael E. Farkouh, Irene O. Nunes,
Chan R. Beals, Sudha S. Shankar
Tawakol and colleagues tested whether high-dose statin treatment would result in greater
reductions in plaque inﬂammation than low-dose statins. Inﬂammation was measured with
2-18F-ﬂuoro-2-deoxy-D-glucose-positron emission tomography/computed tomography
(FDG-PET/CT) in the ascending thoracic aorta and carotid arteries at baseline and at 4 and
12 weeks after randomization to atorvastatin 10 or 80 mg. After 12 weeks, the target-to-
background ratio (TBR) in the wall of the index vessel was signiﬁcantly reduced with
atorvastatin 80 mg, but not with atorvastatin 10 mg. Reductions from baseline in TBR
were seen as early as 4 weeks after randomization. FDG-PET imaging may be useful in
detecting early atherosclerotic treatment effects.
Editorial Comment: Bernhard L. Gerber, p. 918(continued on page A-28)
SEPTEMBER 3, 2013 (continued) A-28CARDIAC IMAGINGVisceral Adiposity Is Associated With Incident Cardiovascular Disease and Cancer 921
Kathryn A. Britton, Joseph M. Massaro, Joanne M. Murabito, Bernard E. Kreger,
Udo Hoffmann, Caroline S. Fox
Britton and colleagues sought to determine whether ectopic fat depots are prospectively
associated with cardiovascular disease, cancer, or all-cause mortality. Participants from the
Framingham Heart Study underwent assessment of fat depots (visceral adipose tissue [VAT],
pericardial adipose tissue, and periaortic adipose tissue) using multidetector computed
tomography, and they were followed longitudinally for a median of 5.0 years. After
multivariable adjustment including body mass index, VAT was associated with cardiovascular
disease and cancer. These results suggest that the link between VAT and obesity-related
complications may involve novel biologic pathways.ADULT CONGENITAL HEART DISEASEPredictors of Complications in Adults With a Systemic Right Ventricle 926
Teun van der Bom, Michiel M. Winter, Maarten Groenink, Hubert W. Vliegen, Petronella G. Pieper,
Arie P. J. van Dijk, Gertjan T. Sieswerda, Jolien W. Roos-Hesselink, Aeilko H. Zwinderman,
Barbara J. M. Mulder, Berto J. Bouma
van der Bom and colleagues sought to identify which patients with a systemic right ventricle
are at risk of clinical events. At baseline, all subjects underwent electrocardiography,
echocardiography, cardiopulmonary exercise testing, and cardiovascular magnetic resonance
imaging (CMR). Clinical events comprised death, vascular events, tricuspid regurgitation
requiring surgery, worsening heart failure, and supraventricular arrhythmia. During follow-
up, the annual risk of clinical events was 12%. Right ventricular end-diastolic volume index
>150 ml/m2 measured by means of CMR or multidetector computed tomography and peak
exercise systolic blood pressure <180 mm Hg were the strongest determinants of clinical
events. The annual event rate in patients with both risk factors was 19% versus 0.9% in
patients without these risk factors.
